In recent trading session, Unicycive Therapeutics Inc (NASDAQ:UNCY) saw 0.95 million shares changing hands at last check today with its beta currently measuring 2.29. Company’s recent per share price level of $0.67 trading at -$0.07 or -10.61% at last check today assigns it a market valuation of $69.12M. That most recent trading price of UNCY’s stock is at a discount of -171.64% from its 52-week high price of $1.82 and is indicating a premium of 70.15% from its 52-week low price of $0.20. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.33 million shares which gives us an average trading volume of 1.55 million if we extend that period to 3-months.
For Unicycive Therapeutics Inc (UNCY), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.07 in the current quarter.
Unicycive Therapeutics Inc (NASDAQ:UNCY) trade information
Upright in the red during last session for losing -10.61%, in the last five days UNCY remained trading in the red while hitting it’s week-highest on Friday, 01/03/25 when the stock touched $0.67 price level, adding 18.79% to its value on the day. Unicycive Therapeutics Inc’s shares saw a change of -16.15% in year-to-date performance and have moved -15.96% in past 5-day. Unicycive Therapeutics Inc (NASDAQ:UNCY) showed a performance of -8.28% in past 30-days. Number of shares sold short was 1.05 million shares which calculate 0.74 days to cover the short interests.
Unicycive Therapeutics Inc (UNCY) estimates and forecasts
Statistics highlight that Unicycive Therapeutics Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company added 38.73% of value to its shares in past 6 months, showing an annual growth rate of 5.00% while that of industry is 16.60. Apart from that, the company came raising its revenue forecast for fiscal year 2025. This year revenue growth is estimated to fall -100.00% from the last financial year’s standing.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -77.09% during past 5 years.
Unicycive Therapeutics Inc (NASDAQ:UNCY)’s Major holders
Insiders are in possession of 6.73% of company’s total shares while institution are holding 38.24 percent of that, with stock having share float percentage of 41.00%. Investors also watch the number of corporate investors in a company very closely, which is 38.24% institutions for Unicycive Therapeutics Inc that are currently holding shares of the company. VIVO CAPITAL, LLC is the top institutional holder at UNCY for having 3.47 million shares of worth $1.74 million. And as of 2024-06-30, it was holding 9.9395 of the company’s outstanding shares.
The second largest institutional holder is LOGOS GLOBAL MANAGEMENT LP, which was holding about 3.47 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.9389 of outstanding shares, having a total worth of $1.74 million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024, the former fund manager was holding 765.0 shares of worth $0.51 million or 0.74% of the total outstanding shares. The later fund manager was in possession of 373.22 shares on Sep 30, 2024, making its stake of worth around $0.25 million in the company or a holder of 0.36% of company’s stock.
